CLINICAL_TRIALS
trial_result
· 2025-10-01
Clinical Trial Update: Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy [Phase 2]
Summary
Phase 2 trial of ofatumumab for minimal residual disease and maintenance therapy in leukemia and lymphoma was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-10-01